The challenge of p53 as prognostic and predictive factor in gliomas

Cancer Treatment Reviews

Volumn 26, Issue 1, 2000, Pages 67-73

  Nieder, C ^a   Petersen, S ^a   Petersen, C ^a   Thames, H D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Astrocytoma; Brain tumors; Glioma; p53 protein; Prognostic factors

Indexed keywords

PROTEIN P53;

APOPTOSIS; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; GENE INACTIVATION; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033956925     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0145     Document Type: Review

References (44)

1. Fine H. A. The basis of current treatment recommendations for malignant glioma. J Neurooncol. 20:1994;111-120.
2. Levin V. A., Silver P., Hannigan J. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 18:1990;321-324.
3. Gundersen S., Lote K., Watne K. A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer. 34:1998;1565-1569.
4. Fueyo J., Gomez-Manzano C., Yung W. K. A., Kyritsis A. P. The functional role of tumor suppressor genes in gliomas. Neurology. 51:1998;1250-1255.
5. Iwadate Y., Fujimoto S., Tagawa M. Association of p53 gene mutation with decreased chemosensitivity in human malignant glioma. Int J Cancer. 69:1996;236-240.
6. Shu H. K., Kim M. M., Chen P. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21 (BAX). Proc Natl Acad Sci USA. 95:1998;14453-14458.
7. Haas-Kogan D. A., Kogan S. S., Yount G. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys. 43:1999;399-403.
8. Baxendine-Jones J., Campbell I., Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol. 16:1997;332-336.
9. Tada M., Matsumoto R., Iggo R. D. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 58:1998;1793-1797.
10. Milner J. Structures and functions of the tumor suppressor p53. Pathol Biol. 45:1997;797-803.
11. Steele R. J., Thompson A. M., Hall P. A., Lane D. P. The p53 tumour suppressor gene. Br J Surg. 85:1998;1460-1467.
12. Amundson S. A., Myers T. G., Fornace A. J. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17:1998;3287-3299.
13. Badie B., Goh C. S., Klaver J. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Ther. 6:1999;155-162.
14. Kirsch D. G., Kastan M. B. Tumor suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 16:1998;3158-3168.
15. Curran W. J., Scott C. B., Horton J. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 85:1993;704-710.
16. J Neurooncol. 9:1990;47-55.
17. Simpson J. R., Horton J., Scott C. B. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys. 26:1993;239-244.
18. Hilton D. A., Love S., Barber R., Ellison D., Sandeman D. R. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery. 42:1998;724-729.
19. Kraus J. A., Bolln C., Wolf H. K. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer. 10:1994;143-149.
20. Newcomb E. W., Cohen H., Lee S. R. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, mdm2 or bcl-2 genes. Brain Pathol. 8:1998;655-667.
21. Bouvier-Labit C., Chinot O., Ochi C., Gambarelli D., Dufour H., Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropath Appl Neurobiol. 24:1998;381-388.
22. Kyritsis A. P., Bondy M. L., Hess K. R. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1:1995;1617-1622.
23. Vital A., Loiseau H., Kantor G. p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract. 194:1998;831-836.
24. Iuzzolino P., Ghimenton C., Nicolato A. p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer. 69:1994;586-591.
25. Shinoda J., Sakai N., Nakatani K., Funakoshi T. Prognostic factors in supratentorial WHO grade Ii astrocytoma in adults. Br J Neurosurg. 12:1998;318-324.
26. AI-Sarraj A., Bridges L. R. p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg. 9:1995;143-149.
27. Bhattacharjee M. B., Bruner J. M. p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neuro Oncol. 32:1997;225-233.
28. Chozick B. S., Pezzullo J. C., Epstein M. H., Finch P. W. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery. 35:1994;831-838.
29. Cunningham J. M., Kimmel D. W., Scheithauer B. W., O'Fallon J. R., Novotny P. J., Jenkins R. B. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg. 86:1997;121-130.
30. Drach L. M., Kammermeier M., Neirich U. Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence. Clin Neuropathol. 15:1996;67-73.
31. Ehrmann J., Kolar Z., Vojtesek B., Kala M., Komenda S., Oulton A. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma. 44:1997;299-304.
32. Ellison D. W., Steart P. V., Bateman A. C., Pickering R. M., Palmer J. D., Weller R. O. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psy. 59:1995;413-419.
33. Hwang S. L., Hong Y. R., Chai C. Y., Lin H. J., Howng S. L. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erb b-2 immunostaining. Kaohsiung J Med Sci. 14:1998;607-615.
34. Montine T. J., Bruner J. M., Vandersteenhoven J. J., Dodge R. K., Burger P. C. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol. 3:1994;240-245.
35. Newcomb E. W., Bhalla S. K., Parrish C. L., Hayes R. L., Cohen H., Miller D. C. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 94:1997;369-375.
36. Rainov N. G., Dobberstein K. U., Bahn H. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro Oncol. 35:1997;13-28.
37. James C. D., Galanis E., Frederick L. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol. 15:1999;547-553.
38. Korkolopoulou P., Christodoulou P., Kouzelis K. MDM 2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 75:1997;1269-1278.
39. Korkolopoulou P., Kouzelis K., Christodoulou P., Papanikolaou A., Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol. 95:1998;617-624.
40. Pollack I. F., Hamilton R. L., Finkelstein S. D. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 57:1997;304-309.
41. Danks R. A., Chopra G., Gonzales M. F., Orian J. M., Kaye A. H. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery. 37:1995;246-254.
42. Schiffer D., Dutto A., Cavalla P. Prognostic factors in oligodendroglioma. Can J Neurol Sci. 24:1997;313-319.
43. Perry A., Jenkins R. B., O'Fallon J. R. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. Cancer. 86:1999;672-683.
44. Mason W., Louis D. N., Cairncross J. G. Chemosensitive gliomas in adults: which ones and why? J Clin Oncol. 15:1997;3423-3426.